Sign in Subscribe

Archive

A collection of 715 issues

Latest

RAF/MEK clamp inhibitor plus cetuximab achieves response in rare RAF1-mutated mCRC

Skip to content The CRC Digest ▸ TREATMENT RAF/MEK clamp inhibitor plus cetuximab achieves response in rare RAF1-mutated mCRC A case report describes a patient with RAF1 S257L-mutated, anti-EGFR-refractory metastatic CRC who achieved radiographic response and performance status improvement with avutometinib (RAF/MEK clamp inhibitor) plus cetuximab. (Oncologist) This content

Australian registry study examines treatment patterns in early-onset CRC with liver metastases

Skip to content The CRC Digest ◇ RESEARCH Australian registry study examines treatment patterns in early-onset CRC with liver metastases A retrospective cohort study using the TRACC registry explored treatment timing, sequencing, and outcomes for early-onset CRC patients (≤50 years) with liver-only metastases compared to late-onset patients. (Med J Aust) This

Digital health interventions may improve nutrition and quality of life in CRC patients

Skip to content The CRC Digest ♥ LIVING WITH CRC Digital health interventions may improve nutrition and quality of life in CRC patients A systematic review and meta-analysis of randomized controlled trials found that digital health interventions showed potential to improve nutritional status and quality of life in patients with colorectal

WhatsApp chatbot outreach improves colorectal cancer screening uptake

Skip to content The CRC Digest ▪ SCREENING WhatsApp chatbot outreach improves colorectal cancer screening uptake A randomized controlled trial found that a theory-based WhatsApp chatbot delivering health education and personalized risk assessment improved CRC screening uptake rates compared to standard text reminders in asymptomatic individuals aged 50-75. (Clin Gastroenterol Hepatol)

Risk-adapted FIT screening intervals may personalize colorectal cancer screening

Skip to content The CRC Digest ▪ SCREENING Risk-adapted FIT screening intervals may personalize colorectal cancer screening A modeling study based on the BLITZ cohort suggests that screening intervals for fecal immunochemical tests could be tailored based on quantitative hemoglobin levels in initially negative tests, stratifying participants into low, medium, and

Antibody-drug conjugate targeting c-MET shows 15.6% response rate in heavily pretreated mCRC

Skip to content The CRC Digest ▸ TREATMENT Antibody-drug conjugate targeting c-MET shows 15.6% response rate in heavily pretreated mCRC Telisotuzumab adizutecan, which delivers a topoisomerase inhibitor to c-MET-expressing tumor cells, achieved an objective response rate of 15.6% in 122 heavily pretreated metastatic colorectal cancer patients in a phase

Sotorasib plus panitumumab and FOLFIRI shows activity in KRAS G12C-mutated metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Sotorasib plus panitumumab and FOLFIRI shows activity in KRAS G12C-mutated metastatic CRC In the phase Ib CodeBreaK 101 trial, the triple combination of sotorasib (a KRAS G12C inhibitor), panitumumab, and FOLFIRI chemotherapy was tested in previously treated patients with KRAS G12C-mutated metastatic

CRC Research Update — August 19, 2026

Today's colorectal cancer research highlights

KRAS G12C Inhibitors in Metastatic CRC: Combination Strategies Reviewed

Skip to content The CRC Digest KRAS G12C Inhibitors in Metastatic CRC: Combination Strategies Reviewed A review article discusses how KRAS G12C mutations account for 3% to 4% of metastatic colorectal cancer cases and explains why combined KRAS G12C and EGFR inhibition may be more effective than monotherapy. (Journal of

Watch-and-Wait After Neoadjuvant Anti-PD-1 in dMMR/MSI-H CRC

Skip to content The CRC Digest Watch-and-Wait After Neoadjuvant Anti-PD-1 in dMMR/MSI-H CRC A multicenter real-world study from four Chinese hospitals evaluated long-term outcomes of a watch-and-wait strategy in stage II/III dMMR/MSI-H colorectal cancer patients who achieved endoscopic complete response after neoadjuvant anti-PD-1 monotherapy. (Frontiers in Immunology)